Literature DB >> 11181384

Efficacy of an evernimicin (SCH27899) in vitro and in an animal model of Lyme disease.

C S Pavia1, G P Wormser, J Nowakowski, A Cacciapuoti.   

Abstract

The MICs of evernimicin at which 90% of Borrelia burgdorferi patient isolates were inhibited ranged from 0.1 to 0.5 microg/ml. Evernimicin was as effective as ceftriaxone against B. burgdorferi in a murine model of experimental Lyme disease. As assessed by culturing the urinary bladders of infected C3H mice, no live Borrelia isolates were recoverable following antibiotic treatment.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11181384      PMCID： PMC90397          DOI： 10.1128/AAC.45.3.936-937.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Practice guidelines for the treatment of Lyme disease. The Infectious Diseases Society of America.

Authors:  G P Wormser; R B Nadelman; R J Dattwyler; D T Dennis; E D Shapiro; A C Steere; T J Rush; D W Rahn; P K Coyle; D H Persing; D Fish; B J Luft
Journal:  Clin Infect Dis       Date:  2000-07       Impact factor: 9.079

2.  EVERNINOMICIN, A NEW ANTIBIOTIC COMPLEX FROM MICROMONOSPORA CARBONACEA.

Authors:  M J WEINSTEIN; G M LUEDEMANN; E M ODEN; G H WAGMAN
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1964

Review 3.  Antimicrobial-drug resistance.

Authors:  H S Gold; R C Moellering
Journal:  N Engl J Med       Date:  1996-11-07       Impact factor: 91.245

4.  Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease.

Authors:  G P Wormser; S Bittker; D Cooper; J Nowakowski; R B Nadelman; C Pavia
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

5.  Activity of sera from patients with Lyme disease against Borrelia burgdorferi.

Authors:  C S Pavia; G P Wormser; G L Norman
Journal:  Clin Infect Dis       Date:  1997-07       Impact factor: 9.079

6.  In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.

Authors:  E Wang; M Simard; Y Bergeron; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  Improving the yield of blood cultures for patients with early Lyme disease.

Authors:  G P Wormser; J Nowakowski; R B Nadelman; S Bittker; D Cooper; C Pavia
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

8.  Failure of treatment with cephalexin for Lyme disease.

Authors:  J Nowakowski; D McKenna; R B Nadelman; D Cooper; S Bittker; D Holmgren; C Pavia; R C Johnson; G P Wormser
Journal:  Arch Fam Med       Date:  2000-06

9.  In vitro inhibition of Borrelia burgdorferi growth by antibodies.

Authors:  A Sadziene; P A Thompson; A G Barbour
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

10.  Antiborrelial activity of serum from rats injected with the Lyme disease spirochete.

Authors:  C S Pavia; V Kissel; S Bittker; F Cabello; S Levine
Journal:  J Infect Dis       Date:  1991-03       Impact factor: 5.226
View more
  3 in total

1.  Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.

Authors:  Charles S Pavia; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Efficacy of short-course ceftriaxone therapy for Borrelia burgdorferi infection in C3H mice.

Authors:  Charles Pavia; Mario A Inchiosa; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

3.  In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease.

Authors:  Venkata Raveendra Pothineni; Mansi B Parekh; Mustafeez Mujtaba Babar; Aditya Ambati; Peter Maguire; Mohammed Inayathullah; Kwang-Min Kim; Lobat Tayebi; Hari-Hara Sk Potula; Jayakumar Rajadas
Journal:  Drug Des Devel Ther       Date:  2018-09-11       Impact factor: 4.162
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.